Published April 10, 2025
| Version v1
Journal article
Open
Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation.
Authors/Creators
- Raposeiras-Roubin S1
- Amat-Santos IJ2
- Rossello X3
- González Ferreiro R4
- González Bermúdez I4
- Lopez Otero D5
- Nombela-Franco L6
- Gheorghe L7
-
Diez JL8
- Baladrón Zorita C2
- Baz JA9
- Muñoz García AJ10
- Vilalta V11
- Ojeda-Pineda S12
- de la Torre Hernández JM13
- Cordoba Soriano JG14
- Regueiro A15
- Bordes Siscar P16
- Salgado Fernández J17
- Garcia Del Blanco B18
- Martín-Reyes R19
-
Romaguera R20
- Moris C21
- García Blas S22
- Franco-Peláez JA23
- Cruz-González I24
- Arzamendi D25
- Romero Rodríguez N26
- Díez-Del Hoyo F27
- Camacho Freire S28
- Bosa Ojeda F29
- Astorga Burgo JC30
- Molina Navarro E31
- Caballero Borrego J32
- Ruiz Quevedo V33
- Sánchez-Recalde Á34
- Peral Disdier V35
- Alegría-Barrero E36
- Torres-Llergo J37
- Feltes G38
- Fernández Díaz JA39
- Cuellas C40
- Jiménez Britez G41
- Sánchez-Rubio Lezcano J42
- Barreiro-Pardal C43
- Núñez-Gil I44
- Abu-Assi E45
- Iñiguez-Romo A9
- Fuster V46
- Ibáñez B47
- 1. Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid; Cardiology Department, University Hospital Álvaro Cunqueiro and Instituto de Investigación Sanitaria Galicia Sur, Vigo, Spain; University of Santiago de Compostela, Santiago de Compostela, Spain
- 2. Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, Madrid; Cardiology Department, University Clinical Hospital of Valladolid, Valladolid, Spain
- 3. Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid; Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, Madrid; Cardiology Department, University Hospital Son Espases and Instituto de Investigación Sanitaria Islas Baleares, Palma de Mallorca, Spain; Universitat de les Illes Balears, Palma, Spain
- 4. Cardiology Department, University Hospital Álvaro Cunqueiro and Instituto de Investigación Sanitaria Galicia Sur, Vigo, Spain
- 5. Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, Madrid; Cardiology Department, University Hospital Montecelo, Pontevedra, Spain
- 6. Cardiology Department, University Clinical Hospital San Carlos, Madrid
- 7. Cardiology Department, University Hospital Puerta del Mar, Cádiz, Spain
- 8. Cardiology Department, University Hospital La Fe, Valencia, Spain
- 9. Cardiology Department, University Hospital Álvaro Cunqueiro and Instituto de Investigación Sanitaria Galicia Sur, Vigo, Spain; Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, Madrid
- 10. Cardiology Department, University Hospital Virgen de la Victoria, Málaga, Spain
- 11. Cardiology Department, University Hospital German Trias i Pujol, Badalona, Spain
- 12. Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, Madrid; Cardiology Department, University Hospital Reina Sofía, Córdoba, Spain
- 13. Cardiology Department, University Hospital Marqués de Valdecilla and Instituto de Investigación Sanitaria Valdecilla, Santander, Spain
- 14. Cardiology Department, University Hospital of Albacete, Albacete, Spain
- 15. Cardiology Department, University Clinical Hospital, Barcelona
- 16. Cardiology Department, University General Hospital of Alicante, Alicante, Spain
- 17. Cardiology Department, University Hospital Juan Canalejo, A Coruña, Spain
- 18. Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, Madrid; Cardiology Department, University Hospital Vall d'Hebron, Barcelona
- 19. Cardiology Department, University Hospital La Luz, Madrid
- 20. Cardiology Department, University Hospital Bellvitge, Barcelona
- 21. Cardiology Department, University Hospital Central de Asturias, Oviedo, Spain
- 22. Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, Madrid; Cardiology Department, University Clinical Hospital of Valencia, Valencia, Spain
- 23. Cardiology Department, University Hospital Fundación Jiménez Díaz and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid
- 24. Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, Madrid; Cardiology Department, University Clinical Hospital of Salamanca, Salamanca, Spain
- 25. Cardiology Department, University Hospital Santa Creu i Sant Pau, Biomedical Research Institute IIB-Sant Pau, Barcelona
- 26. Cardiology Department, University Hospital Virgen del Rocío, Seville, Spain
- 27. Cardiology Department, University Hospital 12 de Octubre, Madrid
- 28. Cardiology Department, University Hospital Juan Ramon Jiménez, Huelva, Spain
- 29. Cardiology Department, University Hospital of Canarias, Tenerife, Spain
- 30. Cardiology Department, University Hospital of Cruces, Baracaldo, Spain
- 31. Cardiology Department, University Hospital Virgen de las Nieves, Granada, Spain
- 32. Cardiology Department, University Hospital San Cecilio, Granada, Spain
- 33. Cardiology Department, University Hospital of Navarra, Pamplona, Spain
- 34. Cardiology Department, University Hospital Ramón y Cajal, Madrid
- 35. Cardiology Department, University Hospital Son Espases and Instituto de Investigación Sanitaria Islas Baleares, Palma de Mallorca, Spain
- 36. Cardiology Department, University Hospital Torrejón and University Francisco de Vitoria, Madrid
- 37. Cardiology Department, University Hospital of Jaen, Jaen, Spain
- 38. Cardiology Department, University Hospital Vithas Arturo Soria, Madrid; University Europea of Madrid, Madrid
- 39. Cardiology Department, University Hospital Puerta del Hierro, Madrid
- 40. Cardiology Department, University Hospital of León, Leon, Spain
- 41. Cardiology Department, Clínica Teknon, Barcelona
- 42. Cardiology Department, University Hospital Miguel Servet, Zaragoza, Spain
- 43. Anesthesiology Department, University Hospital Montecelo, Pontevedra, Spain
- 44. Cardiology Department, University Clinical Hospital San Carlos, Madrid; University Europea of Madrid, Madrid; Cardiology Department, University Hospital of Torrejón, Ribera Salud Group, Madrid
- 45. Cardiology Department, University Hospital of Povisa, Ribera Salud Group, Vigo, Spain
- 46. Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid; Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York
- 47. Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid; Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, Madrid; Cardiology Department, University Hospital Fundación Jiménez Díaz and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid
Description
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart-failure admission among high-risk patients. However, most patients with valvular heart disease, including those undergoing transcatheter aortic-valve implantation (TAVI), have been excluded from randomized trials. METHODS: We conducted this randomized, controlled trial in Spain to evaluate the efficacy of dapagliflozin (at a dose of 10 mg once daily) as compared with standard care alone in patients with aortic stenosis who were undergoing TAVI. All the patients had a history of heart failure plus at least one of the following: renal insufficiency, diabetes, or left ventricular systolic dysfunction. The primary outcome was a composite of death from any cause or worsening of heart failure, defined as hospitalization or an urgent visit, at 1 year of follow-up. RESULTS: A total of 620 patients were randomly assigned to receive dapagliflozin and 637 to receive standard care alone after TAVI; after exclusions, a total of 1222 patients were included in the primary analysis. A primary-outcome event occurred in 91 patients (15.0%) in the dapagliflozin group and in 124 patients (20.1%) in the standard-care group (hazard ratio, 0.72; 95% confidence interval [CI], 0.55 to 0.95; P = 0.02). Death from any cause occurred in 47 patients (7.8%) in the dapagliflozin group and in 55 (8.9%) in the standard-care group (hazard ratio, 0.87; 95% CI, 0.59 to 1.28). Worsening of heart failure occurred in 9.4% and 14.4% of the patients, respectively (subhazard ratio, 0.63; 95% CI, 0.45 to 0.88). Genital infection and hypotension were significantly more common in the dapagliflozin group. CONCLUSIONS: Among older adults with aortic stenosis undergoing TAVI who were at high risk for heart-failure events, dapagliflozin resulted in a significantly lower incidence of death from any cause or worsening of heart failure than standard care alone. (Funded by Instituto de Salud Carlos III and others; ClinicalTrials.gov number, NCT04696185.).
Copyright © 2025 Massachusetts Medical Society.